Business Context and Reporting Period
GE HealthCare Technologies Inc. filed this unaudited Form 10-Q for the three months ended March 31, 2024. The company is a global medical technology, pharmaceutical diagnostics, and digital solutions provider organized into Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The company became independent from GE through the January 2023 spin-off; GE owned approximately 6.7% of outstanding shares as of March 31, 2024.
Financial Performance and Position
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $4.650 billion | $4.707 billion | Down 1%; approximately flat organically |
| Gross profit | $1.902 billion | $1.891 billion | Up $11 million |
| Operating income | $540 million | $559 million | Down 3% |
| Operating margin | 11.6% | 11.9% | Down 30 basis points |
| Net income attributable to GE HealthCare | $374 million | $372 million | Approximately flat |
| Net income margin | 8.0% | 7.9% | Up 10 basis points |
| Diluted EPS | $0.81 | $0.41 | Up $0.40 |
| Adjusted EBIT | $681 million | $664 million | Up 3% |
| Adjusted EBIT margin | 14.7% | 14.1% | Up 50 basis points |
| Cash from operating activities | $419 million | $468 million | Down 11% |
| Free cash flow | $274 million | $325 million | Down 16% |
- Revenue mix: Product revenue declined 3% to $3.045 billion, while service revenue increased 2% to $1.605 billion.
- Segment revenue: Imaging revenue was $2.466 billion, Ultrasound $824 million, PCS $747 million, and PDx $599 million. PDx grew 7%, while Imaging, Ultrasound, and PCS declined 1%, 4%, and 4%, respectively.
- Segment profitability: Imaging Segment EBIT increased 26% to $240 million and PDx increased 15% to $178 million. Ultrasound declined 12% to $182 million and PCS declined 25% to $81 million.
- Costs and margins: Gross profit improved through cost productivity and pricing, partly offset by inflation. R&D expense increased $54 million, while SG&A decreased $24 million.
- Cash and liquidity: Cash, cash equivalents, and restricted cash totaled $2.563 billion at March 31, 2024. The company reported $3.5 billion of undrawn revolving credit facilities and believes available liquidity and operating cash flow will fund operations, debt service, taxes, and investments for at least the next 12 months.
- Debt: Total borrowings were $9.255 billion, compared with $9.442 billion at December 31, 2023. The company repaid $150 million of its term loan during the quarter. A $1.0 billion senior note maturity is due in November 2024. The weighted average interest rate on the Notes and Credit Facilities was 6.08%.
- Capital allocation: Capital expenditures were $145 million. The company paid $14 million in dividends, representing a declared quarterly dividend of $0.03 per common share.
- Remaining performance obligations: RPO was $14.313 billion, down 2% from December 31, 2023. Product RPO was $4.742 billion and services RPO was $9.570 billion.
Material Changes Versus the Prior Comparable Period
- Revenue was lower primarily because of reduced product volume following strong prior-year growth driven by improved supply chain fulfillment, COVID-related demand, and stimulus programs.
- China-region revenue declined 11% to $597 million, with declines across all segments following the prior-year regional stimulus program.
- Operating income declined despite higher gross profit because operating expenses increased, primarily from higher R&D investment and restructuring costs.
- Adjusted EBIT and adjusted net income improved, reflecting cost productivity, pricing, lower SG&A, and lower interest expense.
- The effective tax rate decreased to 24.2% from 29.9%, partly because the prior year included an incremental charge related to withholding and other foreign taxes.
- Operating cash flow and free cash flow declined, primarily due to working-capital changes, benefit payments, annual prepayments, and inventory increases.
- Q1 2024 restructuring costs were $40 million, compared with $12 million in Q1 2023. Approximately $25 million of additional restructuring expense is expected, primarily over the next 12 months.
- Transition Services Agreement costs with GE declined to $53 million net from $108 million.
- Unlike Q1 2023, Q1 2024 did not include a $183 million deemed preferred stock dividend associated with redeemable noncontrolling interests, contributing to the increase in reported diluted EPS.
Guidance, Outlook, Commentary, and Risks
The provided filing text does not state specific full-year revenue, earnings, margin, or cash-flow guidance. Management stated that the company expects existing cash, operating cash generation, capital-market access, and credit facilities to be sufficient for at least the next 12 months.
- Management cited cost productivity, pricing, product investment, and manufacturing capacity expansion as important performance factors.
- Russia and Ukraine-related assets were $141 million at March 31, 2024, and revenue from the two countries was $77 million in the quarter. Export licensing requirements and potential supply disruptions remain relevant risks.
- Key disclosed risks include competition, demand and reimbursement changes, supply-chain disruption, inflation, foreign exchange and interest-rate volatility, geopolitical conflicts, cybersecurity and data-security incidents, product liability, regulatory compliance, intellectual property, and the company’s ability to operate effectively as an independent company.
- The company is subject to ongoing tax audits in multiple jurisdictions, including China, Germany, Norway, the United Kingdom, and the United States.
- The company continues to cooperate with SEC and DOJ reviews related to voluntary self-disclosures concerning potential FCPA violations in China. The duration, outcome, costs, penalties, and remedial actions are not predictable from the filing.
- The company has litigation exposure, including claims involving contracts with the Iraqi Ministry of Health. The filing states that meaningful estimates of potential losses generally cannot be provided at this time.
- On April 1, 2024, after quarter-end, GE HealthCare acquired MIM Software for approximately $258 million net of cash acquired, plus up to $35 million in contingent cash payments. The acquisition was funded with cash on hand and is expected to expand imaging analysis and AI capabilities.
Important Facts for Investors to Verify
- Confirm the company’s full-year guidance, which is not provided in the filing text summarized here.
- Assess the November 2024 $1.0 billion senior note maturity and the company’s refinancing or repayment plan.
- Monitor China demand, regional stimulus effects, and performance in Ultrasound and PCS.
- Evaluate the sustainability of adjusted margin improvement relative to reported operating margin and the level of restructuring and separation costs.
- Track operating cash flow, free cash flow, inventory, receivables, and RPO conversion.
- Review the financial impact and integration progress of the MIM Software acquisition.
- Monitor FCPA reviews, legal proceedings, tax audits, guarantees, and other contingencies for potential future cash costs.
- Consider the effects of foreign currency, interest rates, commodity costs, supply-chain constraints, export licensing, and cybersecurity risks.